
Keywords: Adversity; Biopharmaceuticals; Bispecifics; Cytokine release; Emerging therapies; Gene and cell therapies; Gene editing; Immune-oncology; Immunomodulation; Microbiome; Minimum anticipated biological effect level (MABEL); Monoclonal antibodies; No observed